SOPHiA GENETICS (NASDAQ:SOPH) Hits New 52-Week High – Still a Buy?

Shares of SOPHiA GENETICS SA (NASDAQ:SOPH) hit a new 52-week high during trading on Tuesday . The stock traded as high as $8.84 and last traded at $8.45, with a volume of 655541 shares. The stock had previously closed at $8.65.

SOPHiA GENETICS News Roundup

Here are the key news stories impacting SOPHiA GENETICS this week:

• Positive Sentiment: The stock reached a new 12-month high, signaling strong recent momentum and investor interest. SOPHiA GENETICS Sets New 12-Month High
• Neutral Sentiment: Reported short interest was zero shares as of August 25, implying no measurable short-selling pressure. The data also showed no meaningful change from the prior period, limiting its usefulness as a trading signal.
• Negative Sentiment: CTO Abhimanyu Verma sold 5,000 shares for approximately $44,000 on August 24, reducing his position by 2.82%. Because the sale followed a pre-arranged Rule 10b5-1 plan, it may not reflect a current change in the executive’s outlook. SEC Form 4 filing
• Negative Sentiment: Director Kathy L. Hibbs sold 6,250 shares worth about $54,250 on August 25, decreasing her holdings by 5.71%. The sale adds to near-term insider-selling concerns but was also executed under a 10b5-1 plan. SEC Form 4 filing
• Negative Sentiment: Insider Philippe Menu sold 5,000 shares for approximately $43,400 on August 25, reducing his position by 2.29%. The transaction was pre-planned, which moderates—but does not eliminate—the potential negative signal from multiple insider sales. SEC Form 4 filing

Analyst Ratings Changes

Several equities research analysts have issued reports on SOPH shares. HC Wainwright boosted their price target on shares of SOPHiA GENETICS from $12.00 to $14.00 and gave the company a “buy” rating in a report on Wednesday, August 5th. BTIG Research raised their price objective on shares of SOPHiA GENETICS from $8.00 to $9.00 and gave the stock a “buy” rating in a report on Wednesday, August 5th. Weiss Ratings reiterated a “sell (d-)” rating on shares of SOPHiA GENETICS in a research report on Friday, July 17th. Finally, Zacks Research raised shares of SOPHiA GENETICS to a “hold” rating in a research note on Tuesday, July 21st. Three analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, SOPHiA GENETICS presently has a consensus rating of “Hold” and a consensus price target of $10.00.

SOPHiA GENETICS Price Performance

The company has a 50-day moving average of $6.39 and a 200 day moving average of $5.40. The company has a debt-to-equity ratio of 0.58, a quick ratio of 2.55 and a current ratio of 2.69. The firm has a market cap of $715.58 million, a P/E ratio of -7.42 and a beta of 0.96.

SOPHiA GENETICS (NASDAQ:SOPH) last announced its quarterly earnings results on Wednesday, August 5th. The company reported ($0.26) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.05). SOPHiA GENETICS had a negative net margin of 93.86% and a negative return on equity of 132.47%. The company had revenue of $23.31 million during the quarter, compared to the consensus estimate of $21.72 million. On average, sell-side analysts anticipate that SOPHiA GENETICS SA will post -0.77 EPS for the current year.

Insider Buying and Selling

In related news, insider Zhenyu Xu sold 4,000 shares of SOPHiA GENETICS stock in a transaction dated Thursday, August 13th. The shares were sold at an average price of $7.52, for a total transaction of $30,080.00. Following the completion of the transaction, the insider directly owned 586,887 shares of the company’s stock, valued at $4,413,390.24. This trade represents a 0.68% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Philippe Menu sold 5,000 shares of the business’s stock in a transaction dated Tuesday, August 25th. The shares were sold at an average price of $8.68, for a total transaction of $43,400.00. Following the completion of the transaction, the insider owned 213,387 shares in the company, valued at approximately $1,852,199.16. This trade represents a 2.29% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 334,842 shares of company stock worth $2,110,215 in the last three months. Company insiders own 4.88% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of the company. Sei Investments Co. acquired a new stake in SOPHiA GENETICS during the 1st quarter valued at $1,772,000. AWM Investment Company Inc. acquired a new position in SOPHiA GENETICS in the second quarter worth $9,809,000. 1492 Capital Management LLC acquired a new position in SOPHiA GENETICS in the fourth quarter worth $973,000. Royce & Associates LP bought a new stake in shares of SOPHiA GENETICS during the fourth quarter worth $2,009,000. Finally, Hodges Capital Management Inc. bought a new stake in shares of SOPHiA GENETICS during the first quarter worth $2,157,000. Institutional investors own 31.59% of the company’s stock.

About SOPHiA GENETICS

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.